Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
C
083790
vs
K
KOSPI 200
Over the past 12 months, CrystalGenomics Inc has underperformed KOSPI 200, delivering a return of -40% compared to KOSPI 200's +125% growth.
Stocks Performance
083790 vs KOSPI 200
Performance Gap
083790 vs KOSPI 200
Performance By Year
083790 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CrystalGenomics Inc
Glance View
CrystalGenomics is a South Korean biopharmaceutical company that focuses on discovering and developing new medicines, especially small-molecule drugs. Its business is built around researching drug candidates, running clinical development, and moving promising compounds toward approval rather than running a large consumer-facing drug brand. The company makes money mainly through drug development partnerships, licensing deals, and sales of any approved medicines or related rights. Its main customers and partners are other pharmaceutical companies, hospitals, and healthcare markets that use or distribute the medicines it helps develop. In practice, CrystalGenomics sits in the middle of the drug value chain: it creates early-stage drug assets and then works with larger drugmakers to commercialize them. What makes its business different is that it is a research-driven biotech, so most of its value comes from a pipeline of drug candidates and the know-how needed to advance them. That means the company depends on scientific progress, regulatory approval, and partner interest, rather than on broad manufacturing or retail distribution.